Hyperlipidemia Abnormal
obesity
Smoking HT Diabetes Stress Number of
treatments
Risk benefits
Renal artery
denervation
Benefit triglycerides &
HDL slight
No No YES Reduces Insulin
resistance
Unknown 1 Risk of vascular damage- no
further treatment
Drug
treatments
Yes No mortality for ↓
triglycerides
Maybe Maybe YES with mortality data No primary endpoint
CV mortality data
Maybe in patients
after MI
6 different
drugs
Lifelong therapy
HT: Hypertension
HDL: High Density Lipoprotein Adapted from INTERHEART;
CV: Cardiovascular Juni P, et al. Lancet 2004; 364:
MI: Myocardial Infarction 2021-9
Comparing important cardiovascular risk factor treatment options, reveals the potential of renal artery denervation as one treatment that may have many benefits in reducing
cardio-metabolic risk. However, risk to patient with renal artery denervation must be further evaluated with large trials for safety and long term concerns
Table 1: Strategies for cardiovascular global risk reduction.